Dr. Gerald Marshall Isbell III, MD

Dr. Isbell practices at William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System.

Dr. Isbell's NPI, 1093774853, was assigned on March 21, 2006. Dr. Isbell graduated from Wake Forest School of Medicine in 1982. Dr. Isbell's Texas license number on file is H1289.

Dr. Isbell's primary practice is William P. Clements Jr. University Hospital, at 6201 Harry Hines Blvd, Dallas, TX 75390 in Dallas County. The practice phone is (214) 633-5555.

Dr. Isbell's primary practice is William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System. The medical group on file is University of Texas Southwestern Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Isbell practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Isbell's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Isbell is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Isbell has a license on file in Texas.

Dmand AI lists acid reflux, chronic indigestion, chronic inflammatory bowel disease (IBD), colonoscopy, gastroduodenitis, intestinal diverticulosis, intestinal or bowel obstruction and irritable bowel syndrome (IBS) among the conditions Dr. Isbell treats.

CMS data shows 172 Medicare services from Dr. Isbell across 7 procedure codes in 2024, for 174 Medicare patients. Medicare paid $17,257 for them.

CMS counts 174 Medicare patients who saw Dr. Isbell in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Isbell's median patient age at 64, with 57% women.

In 2024, Dr. Isbell wrote 528 Medicare Part D claims for 201 patients. 76% of them were for generic drugs. CMS names the drug for 390 of them, across 13 drugs with 11 or more claims each, at $55,720 in total drug cost. In 2023, CMS named 343 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Isbell for performance year 2024, reported as part of a group. Dr. Isbell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Isbell as offering telehealth. CMS counts 58 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Isbell, more than 66% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Isbell. The most frequent topics are Colonic Neoplasms. Dr. Isbell's most frequent co-authors are Frank L. Lanza, MD and Patrick M. Lynch, JD, MD.

CMS Open Payments shows 126 general payments to Dr. Isbell from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $481.

Dr. Isbell graduated from Wake Forest School of Medicine in 1982.

Dr. Isbell is in network with 20 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.